Literature DB >> 26337810

Clinical Characteristics and Outcomes of Cardiomyopathy in Barth Syndrome: The UK Experience.

Sok-Leng Kang1, Jonathan Forsey2, Declan Dudley3, Colin G Steward4, Beverly Tsai-Goodman3.   

Abstract

Barth syndrome (BTHS) is an X-linked disorder characterised by cardiomyopathy, neutropenia, skeletal myopathy and growth delay. This study describes the UK national clinical experience and outcome of cardiomyopathy in BTHS. The clinical course and echocardiographic changes of all patients with BTHS in the UK were reviewed from 2004 to 2014. In addition, strain analysis using 2D speckle tracking echocardiography was performed to further assess left ventricular function in the most recent follow-up. At last follow-up, 22 of 27 patients were alive with a median age of 12.6 (2.0-23.8) years; seven underwent cardiac transplantation at a median age of 2 (0.33-3.6) years, and five died (18.5%) at a median age of 1.8 (0.02-4.22) years. All deaths were related to cardiomyopathy or its management. Left ventricular diastolic dimension and systolic function measured by fractional shortening tended to normalise and stabilise after the first 3 years of life in the majority of patients. However, patients with BTHS (n = 16) had statistically significant reduction in global longitudinal and circumferential strain compared to controls (n = 18), (p < 0.001), despite apparent normal conventional measures of function. There was also reduced or reversed apical rotation and reduced left ventricular twist. Sustained ventricular arrhythmia was not seen at follow-up. Cardiac phenotype in BTHS is variable; however, longer-term outcome in our cohort suggests good prognosis after the first 5 years of life. Most patients appeared to have recovered near normal cardiac function by conventional echocardiographic measures, but strain analysis showed abnormal myocardial deformation and rotational mechanics.

Entities:  

Keywords:  Barth syndrome; Cardiomyopathies; Echocardiography; Heart failure; Prognosis

Mesh:

Year:  2015        PMID: 26337810     DOI: 10.1007/s00246-015-1260-z

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  31 in total

Review 1.  Twist and untwist mechanics of the left ventricle.

Authors:  Partho P Sengupta; Bijoy K Khandheria; Jagat Narula
Journal:  Heart Fail Clin       Date:  2008-07       Impact factor: 3.179

2.  Impaired cardiac reserve and severely diminished skeletal muscle O₂ utilization mediate exercise intolerance in Barth syndrome.

Authors:  Carolyn T Spencer; Barry J Byrne; Randall M Bryant; Renee Margossian; Melissa Maisenbacher; Petar Breitenger; Paul B Benni; Sharon Redfearn; Edward Marcus; W Todd Cade
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-26       Impact factor: 4.733

3.  Cardiac and clinical phenotype in Barth syndrome.

Authors:  Carolyn T Spencer; Randall M Bryant; Jane Day; Iris L Gonzalez; Steven D Colan; W Reid Thompson; Julie Berthy; Sharon P Redfearn; Barry J Byrne
Journal:  Pediatrics       Date:  2006-07-17       Impact factor: 7.124

4.  The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study.

Authors:  Amy E Roberts; Connie Nixon; Colin G Steward; Kimberly Gauvreau; Melissa Maisenbacher; Matthew Fletcher; Judith Geva; Barry J Byrne; Carolyn T Spencer
Journal:  Am J Med Genet A       Date:  2012-10-08       Impact factor: 2.802

5.  X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene.

Authors:  April N Brady; Bahig M Shehata; Paul M Fernhoff
Journal:  Prenat Diagn       Date:  2006-05       Impact factor: 3.050

6.  Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid.

Authors:  I Ostman-Smith; G Brown; A Johnson; J M Land
Journal:  Br Heart J       Date:  1994-10

7.  Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth.

Authors:  C G Steward; R A Newbury-Ecob; R Hastings; S F Smithson; B Tsai-Goodman; O W Quarrell; W Kulik; R Wanders; M Pennock; M Williams; J L Cresswell; I L Gonzalez; P Brennan
Journal:  Prenat Diagn       Date:  2010-10       Impact factor: 3.050

8.  Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.

Authors:  Ann Bowron; Julie Honeychurch; Maggie Williams; Beverley Tsai-Goodman; Nicol Clayton; Lucy Jones; Graham J Shortland; Shakeel A Qureshi; Simon J R Heales; Colin G Steward
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

Review 9.  Barth syndrome.

Authors:  Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward
Journal:  Orphanet J Rare Dis       Date:  2013-02-12       Impact factor: 4.123

10.  A novel X-linked gene, G4.5. is responsible for Barth syndrome.

Authors:  S Bione; P D'Adamo; E Maestrini; A K Gedeon; P A Bolhuis; D Toniolo
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

View more
  14 in total

1.  Measurement of genetic diseases as a cause of mortality in infants receiving whole genome sequencing.

Authors:  Stephen F Kingsmore; Audrey Henderson; Mallory J Owen; Michelle M Clark; Christian Hansen; David Dimmock; Christina D Chambers; Laura L Jeliffe-Pawlowski; Charlotte Hobbs
Journal:  NPJ Genom Med       Date:  2020-11-02       Impact factor: 8.617

2.  Longitudinal Observational Study of Cardiac Outcome Risk Factor Prediction in Children, Adolescents, and Adults with Barth Syndrome.

Authors:  Shahryar Chowdhury; Lanier Jackson; Barry J Byrne; Randall M Bryant; W Todd Cade; Tammy Lane Churchill; Julia Buchanan; Carolyn Taylor
Journal:  Pediatr Cardiol       Date:  2022-03-03       Impact factor: 1.838

Review 3.  A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?

Authors:  Mindong Ren; Paighton C Miller; Michael Schlame; Colin K L Phoon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-10-11       Impact factor: 4.733

4.  Myocardial glucose and fatty acid metabolism is altered and associated with lower cardiac function in young adults with Barth syndrome.

Authors:  William Todd Cade; Richard Laforest; Kathryn L Bohnert; Dominic N Reeds; Adam J Bittel; Lisa de Las Fuentes; Adil Bashir; Pamela K Woodard; Christina A Pacak; Barry J Byrne; Robert J Gropler; Linda R Peterson
Journal:  J Nucl Cardiol       Date:  2019-11-08       Impact factor: 3.872

5.  Peak oxygen uptake (VO2peak) across childhood, adolescence and young adulthood in Barth syndrome: Data from cross-sectional and longitudinal studies.

Authors:  William Todd Cade; Kathryn L Bohnert; Dominic N Reeds; Linda R Peterson; Adam J Bittel; Adil Bashir; Barry J Byrne; Carolyn L Taylor
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

Review 6.  Role of Tafazzin in Mitochondrial Function, Development and Disease.

Authors:  Michael T Chin; Simon J Conway
Journal:  J Dev Biol       Date:  2020-05-23

7.  Aetiology and 30-Year Long-Term Outcome of Children with Cardiomyopathy Necessitating Heart Transplantation.

Authors:  Martin Zschirnt; Josef Thul; Hakan Akintürk; Klaus Valeske; Dietmar Schranz; Susanne Skrzypek; Matthias Müller; Christian Jux; Andreas Hahn; Stefan Rupp
Journal:  J Pers Med       Date:  2020-11-27

Review 8.  Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies.

Authors:  Quynh Nguyen; Kenji Rowel Q Lim; Toshifumi Yokota
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

9.  Measurement of genetic diseases as a cause of mortality in infants receiving whole genome sequencing.

Authors:  Stephen F Kingsmore; Audrey Henderson; Mallory J Owen; Michelle M Clark; Christian Hansen; David Dimmock; Christina D Chambers; Laura L Jeliffe-Pawlowski; Charlotte Hobbs
Journal:  NPJ Genom Med       Date:  2020-11-02       Impact factor: 8.617

Review 10.  Clinical trials in mitochondrial disorders, an update.

Authors:  Mohammed Almannai; Ayman W El-Hattab; May Ali; Claudia Soler-Alfonso; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2020-10-06       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.